Results 291 to 300 of about 1,678,519 (353)

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The face of remission induction

British Journal of Haematology, 2019
SummaryAcute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient‐related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little ...
Shilpa Paul, Caitlin R. Rausch, Elias J. Jabbour   +2 more
openaire   +3 more sources

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis

Gut, 2022
Objective There are numerous biological therapies and small molecules licensed for luminal Crohn’s disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis.
B. Barberio, D. Gracie, C. Black, A. Ford   +3 more
semanticscholar   +1 more source

The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.

The Lancet Gastroenterology and Hepatology, 2021
BACKGROUND The Crohn's disease exclusion diet (CDED) with partial enteral nutrition is effective for induction of remission in children with mild-to-moderate Crohn's disease. We aimed to assess the CDED in adults with Crohn's disease. METHODS We did an
H. Yanai, A. Levine, A. Hirsch, R. S. Boneh, U. Kopylov, H. B. Eran, N. Cohen, Y. Ron, I. Goren, H. Leibovitzh, J. Wardi, E. Zittan, T. Ziv-Baran, L. Abramas, N. Fliss-Isakov, B. Raykhel, T. P. Gik, I. Dotan, N. Maharshak   +18 more
semanticscholar   +1 more source

Remission induction, maintenance, and endoscopic outcome with oral 5‐aminosalicylic acid in intestinal Behçet's disease

Journal of Gastroenterology and Hepatology, 2019
Oral 5‐aminosalicylic acid (5‐ASA) is recommended for the therapy of mild to moderate intestinal Behçet's disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5‐ASA are unknown. We investigated remission induction at 8 weeks,
Hiroto Kinoshita, H. Nishioka, A. Ikeda, K. Ikoma, Y. Sameshima, H. Ohi, M. Tatsuno, J. Kouyama, C. Kawamoto, T. Mitsui, Y. Tamura, Y. Hashimoto, M. Nishio, T. Ogashiwa, Y. Saigusa, S. Maeda, H. Kimura, R. Kunisaki, K. Koike   +18 more
semanticscholar   +1 more source

Optimal induction and post-remission therapy for AML in first remission

Hematology, 2009
AbstractApproximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML). The median age at presentation has been steadily increasing over the past few decades and now is approaching 70 years. Although considerable progress has been made over the past 3 decades in the therapy of AML, two thirds of young adults still ...
openaire   +2 more sources

Budesonide for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2015
Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission ...
Ali, Rezaie, M Ellen, Kuenzig, Eric I, Benchimol, Anne Marie, Griffiths, Anthony R, Otley, A Hillary, Steinhart, Gilaad G, Kaplan, Cynthia H, Seow   +7 more
openaire   +2 more sources

Induction of Durable Remission in Ocular Inflammatory Diseases

European Journal of Ophthalmology, 2009
Purpose To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission. Methods Retrospective cohort study. The records of 399 patients with ocular inflammatory diseases treated with systemic immunomodulatory therapy (IMT) at the Massachusetts Eye Research and Surgery Institution were reviewed ...
R A, Cervantes-Castaneda, P, Bhat, E, Fortuna, S, Acevedo, C S, Foster   +4 more
openaire   +2 more sources

HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIA

The Lancet, 1977
28 adult patients with acute myeloid leukaemia (A.M.L.) received T.A.D., a high-dose sequential chemotherapeutic remission-induction regimen consisting of 7-day courses of cytosine arabinoside, 6-thioguanine, and daunorubicin. Overall response-rate was 82%. 22 patients (79%) achieved complete remission, and 1 had a partial remission.
R P, Gale, M J, Cline
openaire   +2 more sources